Answers are grounded in this paper and cite their sources.
BACKGROUND: ε4 carrier status in individuals with subjective cognitive decline (SCD). METHODS: We retrospectively analyzed baseline data from the Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia from Subjective Cognitive Decline. Plasma levels of the amyloid beta (Aβ) 42/40 ratio, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) 181 were quantified using Single Molecule Array technology. We assessed predictive performance of plasma biomarkers for amyloid PET outcomes using receiver operating characteristic analysis and linear regression models. CONCLUSION: genotype when interpreting plasma biomarker results for AD diagnosis in individuals with SCD. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0003397.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: